Trials / Completed
CompletedNCT02162264
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 8,662 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donepezil Hydrochloride | Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms. |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2015-05-30
- Completion
- 2016-07-22
- First posted
- 2014-06-12
- Last updated
- 2018-09-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02162264. Inclusion in this directory is not an endorsement.